Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma

2015, Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013, Lancet, 386, 743, 10.1016/S0140-6736(15)60692-4 Paik, 2020, Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD, Hepatology, 72, 1605, 10.1002/hep.31173 Valery, 2018, Projections of primary liver cancer to 2030 in 30 countries worldwide, Hepatology, 67, 600, 10.1002/hep.29498 Masarone, 2016, Epidemiology and natural history of alcoholic liver disease, Rev Recent Clin Trials, 11, 167, 10.2174/1574887111666160810101202 Sanyal, 2019, The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials, Hepatology, 70, 1913, 10.1002/hep.30664 Fazel, 2016, Epidemiology and natural history of non-alcoholic fatty liver disease, Metabolism, 65, 1017, 10.1016/j.metabol.2016.01.012 Vernon, 2011, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Aliment Pharmacol Ther, 34, 274, 10.1111/j.1365-2036.2011.04724.x Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 Younossi, 2019, The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis, J Hepatol, 71, 793, 10.1016/j.jhep.2019.06.021 Boursier, 2020, Fib-4 and Fibroscan can identify patients with NAFLD who are at risk of liver related events: Results of a longitudinal analysis with comparison with liver biopsy, Hepatology, 72 Barritt, 2020, Fibrosis assessed by non-invasive is similar to liver biopsy for predicting clinical outcomes: a Target- NASH study, Hepatology, 72 Younossi, 2018, Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, 11, 10.1038/nrgastro.2017.109 Le, 2020, Prevalence and risk factors of hepatic steatosis and fibrosis in American adults: a population based study, Hepatolgy, 72 Li, 2019, Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis, Lancet Gastroenterol Hepatol, 4, 389, 10.1016/S2468-1253(19)30039-1 Ye, 2020, Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis, Lancet Gastroenterol Hepatol, 5, 739, 10.1016/S2468-1253(20)30077-7 Eguchi, 2020, Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: a focused literature review, JGH Open, 4, 808, 10.1002/jgh3.12349 Balakrishnan, 2021, Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 19, 10.1016/j.cgh.2020.04.067 Ye, 2019, Sex-based differences in the association between nonalcoholic fatty liver disease and mortality, Clin Gastroenterol Hepatol, 17, 211, 10.1016/j.cgh.2018.08.002 Younossi, 2016, The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe, Hepatology, 64, 1577, 10.1002/hep.28785 Younossi, 2018, Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Clin Liver Dis, 22, 1, 10.1016/j.cld.2017.08.001 Younossi, 2019, Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 17, 10.1016/j.cgh.2019.02.024 Younossi, 2018, Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib, Liver Int, 38, 1849, 10.1111/liv.13706 Golabi, 2019, Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality, Clin Diab, 37, 65, 10.2337/cd18-0026 Golabi, 2020, Mortality of NAFLD according to the body composition and presence of metabolic abnormalities, Hepatol Commun, 4, 1136, 10.1002/hep4.1534 Ye, 2020, Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis, Lancet Gastroenterol Hepatol, 5, 739, 10.1016/S2468-1253(20)30077-7 Younossi, 2020, Epidemiology of chronic liver diseases in the USA in the past three decades, Gut, 69, 564, 10.1136/gutjnl-2019-318813 Noureddin, 2018, NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances, Am J Gastroenterol, 113, 1649, 10.1038/s41395-018-0088-6 Younossi, 2021, Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States, Clin Gastroenterol Hepatol, 19, 10.1016/j.cgh.2020.05.064 McGlynn, 2011, The global epidemiology of hepatocellular carcinoma: present and future, Clin Liver Dis, 15, 223, 10.1016/j.cld.2011.03.006 Hashimoto, 2009, Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, J Gastroenterol, 44, 89, 10.1007/s00535-008-2262-x Kim, 2018, Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: a real-world experience from 1998 to 2015, Cancer, 124, 2588, 10.1002/cncr.31373 Younossi, 2015, Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009, Hepatology, 62, 1723, 10.1002/hep.28123 Hardy, 2020, The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease, Contemp Clin Trials, 98, 106175, 10.1016/j.cct.2020.106175 Said, 2017, Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma, World J Clin Oncol, 8, 429, 10.5306/wjco.v8.i6.429 Davitkov, 2020, Moderate degree on liver stiffness in NAFLD is associated with an increased risk of Hepatocellular carcinoma, Hepatology, 72 White, 2012, Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review, Clin Gastroenterol Hepatol, 10, 10.1016/j.cgh.2012.10.001 Paradis, 2009, Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis, Hepatology, 49, 851, 10.1002/hep.22734 Perumpail, 2015, Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience, Dig Dis Sci, 60, 3142, 10.1007/s10620-015-3821-7 Bengtsson, 2019, Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis, Liver Int, 39, 1098, 10.1111/liv.14087 Hester, 2020, Among Medicare patients with hepatocellular carcinoma, non-alcoholic fatty liver disease is the most common etiology and cause of mortality, J Clin Gastroenterol, 54, 459, 10.1097/MCG.0000000000001172 Sayiner, 2017, Variables associated with inpatient and outpatient resource utilization among Medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis, J Clin Gastroenterol, 51, 254, 10.1097/MCG.0000000000000567 Marrero, 2018, Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases, Hepatology, 68, 723, 10.1002/hep.29913 Loomba, 2020, AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Clinical practice update, Gastro, 158, 10.1053/j.gastro.2019.12.053 Cholankeril, 2017, Hepatocellular carcinoma in non-alcoholic steatohepatitis: current knowledge and implications for management, World J Hepatol, 9, 533, 10.4254/wjh.v9.i11.533 Zoller, 2016, Nonalcoholic fatty liver disease and hepatocellular carcinoma, Metabolism, 65, 1151, 10.1016/j.metabol.2016.01.010 Berkan-Kawinska, 2020, Hepatocellular carcinoma in non-alcohol fatty liver disease–changing trends and specific challenges, Curr Med Res Opin, 36, 235, 10.1080/03007995.2019.1683817 Wang, 2012, Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies, Int J Canc, 130, 1639, 10.1002/ijc.26165 Chettouh, 2015, Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma, Liver Int, 35, 2203, 10.1111/liv.12903 Nyberg, 2020, The natural history of NAFLD, a community-based study at a large health care delivery system in the United States, Hepatol Commun, 5, 83, 10.1002/hep4.1625 Llovet, 2003, Hepatocellular carcinoma, Lancet, 362, 1907, 10.1016/S0140-6736(03)14964-1 Raff, 2015, Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases, J Clin Transl Hepatol, 3, 9, 10.14218/JCTH.2015.00001 Larsson, 2007, Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies, Br J Canc, 97, 1005, 10.1038/sj.bjc.6603932 Connell, 2016, Advanced hepatocellular cancer: the current state of future research, Curr Treat Options Oncol, 17, 43, 10.1007/s11864-016-0415-3 Loomba, 2020, Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data, Aliment Pharmacol Ther, 51, 1149, 10.1111/apt.15679 Canbay, 2020, Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease, Aliment Pharmacol Ther, 52, 1185, 10.1111/apt.16016 Eguchi, 2020, Hepatocellular carcinoma and other complications of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: a structured review of published works, Hepatol Res Diehl, 2005, Cytokines and the pathogenesis of non-alcoholic steatohepatitis, Gut, 54, 303, 10.1136/gut.2003.024935 Wang, 2009, Nonalcoholic steatohepatitis induced by a high-fat diet promotes diethylnitrosamine-initiated early hepatocarcinogenesis in rats, Int J Canc, 124, 540, 10.1002/ijc.23995 Park, 2010, Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression, Cell, 140, 197, 10.1016/j.cell.2009.12.052 Kamada, 2007, Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model, J Hepatol, 47, 556, 10.1016/j.jhep.2007.03.020 Hashimoto, 2012, Hepatocellular carcinoma in non-alcoholic steatohepatitis: growing evidence of an epidemic?, Hepatol Res, 42, 1, 10.1111/j.1872-034X.2011.00872.x Marnett, 2000, Oxyradicals and DNA damage, Carcinogenesis, 21, 361, 10.1093/carcin/21.3.361 Hu, 2002, The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma, Carcinogenesis, 23, 1781, 10.1093/carcin/23.11.1781 Feng, 2003, Mutational spectrum and genotoxicity of the major lipid peroxidation product, trans-4-hydroxy-2-nonenal, induced DNA adducts in nucleotide excision repair-proficient and -deficient human cells, Biochemistry, 42, 7848, 10.1021/bi034431g Xu, 2005, Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia, Proc Natl Acad Sci U S A, 102, 4120, 10.1073/pnas.0500660102 Siegel, 2009, Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link, Cancer, 115, 5651, 10.1002/cncr.24687 Calle, 2003, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med, 348, 1625, 10.1056/NEJMoa021423 Shoelson, 2007, Obesity, inflammation, and insulin resistance, Gastroenterology, 132, 2169, 10.1053/j.gastro.2007.03.059 Stickel, 2010, Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications, Gut, 59, 1303, 10.1136/gut.2009.199661 Marra, 2002, Leptin and liver fibrosis: a matter of fat, Gastroenterology, 122, 1529, 10.1053/gast.2002.33369 Perumpail, 2015, Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: potential mechanistic pathways, World J Hepatol, 7, 2384, 10.4254/wjh.v7.i22.2384 Hirose, 2020, Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: lean versus overweight patients, PloS One, 15, 10.1371/journal.pone.0241770 Morse, 2019, The role of angiogenesis in hepatocellular carcinoma, Clin Canc Res, 25, 912, 10.1158/1078-0432.CCR-18-1254 Kim, 2002, Hypoxia-induced angiogenesis in human hepatocellular carcinoma, J Mol Med, 30, 703, 10.1007/s00109-002-0380-0 Von Marschall, 2001, Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma, Gut, 48, 87, 10.1136/gut.48.1.87 Lee, 2019, STAT3: an emerging therapeutic target for hepatocellular carcinoma, Cancers (Basel), 11, 1646, 10.3390/cancers11111646 Choi, 2018, Expression patterns of STAT3, ERK and estrogen-receptor α are associated with development and histologic severity of hepatic steatosis: a retrospective study, Diagn Pathol, 13, 23, 10.1186/s13000-018-0698-8 Kim, 2020, Rates and predictors of undergoing different hepatocellular screening tests in patients with cirrhosis, Hepatolgy, 72 Leung, 2015, Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease, World J Gastroenterol, 21, 1189, 10.3748/wjg.v21.i4.1189 Mohamad, 2016, Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis, Hepatol Int, 10, 632, 10.1007/s12072-015-9679-0 Gergely, 2020, Insurance status and disease severity are associated with HCC screening adherence, Hepatology, 72 Khan, 2020, Missed opportunities for hepatocellular carcinoma (HCC) screening and surveillance amongst veterans subsequently diagnosed with HCC, Hepatology, 72 Rai, 2020, Lack of liver disease awareness: important contributor to late state hepatocellular carcinoma, Hepatology, 72 Biswas, 2020, Poor liver disease awareness among adults with NAFLD in the United States, Hepatology, 72 Kawada, 2009, Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis, J Gastroenterol, 44, 1190, 10.1007/s00535-009-0112-0 Starley, 2010, Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection, Hepatology, 51, 1820, 10.1002/hep.23594 Guzman, 2008, Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?, Arch Pathol Lab Med, 132, 1761, 10.5858/132.11.1761 Baffy, 2012, Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace, J Hepatol, 56, 1384, 10.1016/j.jhep.2011.10.027 Reig, 2019, Should patients with NAFLD/NASH be surveyed for HCC?, Transplantation, 103, 39, 10.1097/TP.0000000000002361 Younossi, 2018, Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis, Hepatology, 68, 349, 10.1002/hep.29721 Anstee, 2019, Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials, Hepatology, 70, 1521, 10.1002/hep.30842 Younossi, 2020, The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis, Gastroenterology Younossi, 2020, Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: expert panel recommendations, Am J Gastroenterol Vallet-Pichard, 2007, FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest, Hepatology, 46, 32, 10.1002/hep.21669 McPherson, 2017, Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis, Am J Gastroenterol, 112, 740, 10.1038/ajg.2016.453 Tapper, 2014, Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease, Gastroenterol Rep, 2, 276, 10.1093/gastro/gou034 Kanwal, 2018, Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease, Gastroenterology, 155, 10.1053/j.gastro.2018.08.024 NAFLD score (https://nafldscore.com/). Accessed January 23, 2021. The ELF Test. https://www.siemens-healthineers.com/laboratory-diagnostics/assays-by-diseases-conditions/liver-disease/elf-test. Accessed on 1/25/21. Younossi, 2020, Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices, Aliment Pharmacol Ther, 52, 513, 10.1111/apt.15830 Kulik, 2019, Epidemiology and management of hepatocellular carcinoma, Gastroenterology, 156, 477, 10.1053/j.gastro.2018.08.065 Younossi, 2021, Identification of high-risk patients with nonalcoholic fatty liver disease using noninvasive tests from primary care and endocrinology real-world practices, Clin Transl Gastroenterol, 12, e00340, 10.14309/ctg.0000000000000340 Younossi, 2019, Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial, Lancet, 394, 2184, 10.1016/S0140-6736(19)33041-7 Harrison, 2020, STELLAR-3 and STELLAR-4 Investigators. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials, J Hepatol, 73, 26, 10.1016/j.jhep.2020.02.027 Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet, 387, 679, 10.1016/S0140-6736(15)00803-X Younossi, 2021, AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review, Gastroenterology, 160, 912, 10.1053/j.gastro.2020.11.051 Negro, 2020, Natural history of NASH and HCC, Liver Int, 40, 72, 10.1111/liv.14362 Laursen, 2019, Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects, World J Hepatol, 11, 138, 10.4254/wjh.v11.i2.138 Quezada, 2020, Bariatric surgery in cirrhotic patients: a matched case-control study, Obes Surg, 30, 4724, 10.1007/s11695-020-04929-y Younus, 2020, Bariatric surgery in cirrhotic patients: is it safe?, Obes Surg, 30, 1241, 10.1007/s11695-019-04214-7 Golabi, 2017, Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities, Medicine (Baltimore), 96, 10.1097/MD.0000000000005904 Singh, 2013, Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis, Am J Gastroenterol, 108, 881, 10.1038/ajg.2013.5 Targher, 2016, Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis, J Hepatol, 65, 589, 10.1016/j.jhep.2016.05.013 Nelson, 2009, A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized, placebo-controlled trial, J Clin Gastroenterol, 43, 900, 10.1097/MCG.0b013e31819c392e Murff, 2018, Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer, Cancer Causes Control, 29, 823, 10.1007/s10552-018-1058-4 Ma, 2017, Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients, Medicine (Baltimore), 96, e6888, 10.1097/MD.0000000000006888 Arvind, 2020, Incidence of hepatocellular carcinoma is decreased in thiazolidinedione users and increased in alpha-glucodidase inhibitor users: a systematic review and meta-analysis, Hepatology, 72 Cusi, 2016, Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial, Ann Intern Med, 165, 305, 10.7326/M15-1774 Newsome, 2021, NN9931-4296 investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis, N Engl J Med, 384, 1113, 10.1056/NEJMoa2028395 Santambrogio, 2016, Long-term outcome of laparoscopic ablation therapies for unresectable hepatocellular carcinoma: a single European center experience of 426 patients, Surg Endosc, 30, 2103, 10.1007/s00464-015-4468-3 Casadei Gardini, 2018, Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival, Onco Targets Ther, 11, 6555, 10.2147/OTT.S170836 Gluer, 2012, Systematic review of actual 10-year survival following resection for hepatocellular carcinoma, HPB (Oxford), 14, 285, 10.1111/j.1477-2574.2012.00446.x Woodrell, 2018, Palliative care for people with hepatocellular carcinoma, and specific benefits for older adults, Clin Ther, 40, 512, 10.1016/j.clinthera.2018.02.017 Yoo, 2014, Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases, PLoS One, 9, e113926, 10.1371/journal.pone.0113926 Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Bruix, 2017, Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies, J Hepatol, 67, 999, 10.1016/j.jhep.2017.06.026 Kudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1 Zhu, 2015, Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial, Lancet Oncol, 16, 859, 10.1016/S1470-2045(15)00050-9 King, 2017, Sorafenib for the treatment of advanced hepatocellular cancer - a UK audit, Clin Oncol (R Coll Radiol), 29, 256, 10.1016/j.clon.2016.11.012 El-Khoueiry, 2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 389, 2492, 10.1016/S0140-6736(17)31046-2 Kudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1 FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma. Obtained from the world wide web at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-hepatocellular-carcinoma. Last accessed on 3/30/2021. Finn, 2020, IMbrave150 investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, N Engl J Med, 382, 1894, 10.1056/NEJMoa1915745 FDA. FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Obtained from the world wide web at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma. Last accessed on 3/30/2021. Wang, 2020, Causes and trends in liver disease and hepatocellular carcinoma among men and women who received liver transplants in the U.S., 2010-2019, PloS One, 15 Golabi, 2018, Liver transplantation (LT) for cryptogenic cirrhosis (CC) and nonalcoholic steatohepatitis (NASH) cirrhosis: data from the scientific registry of transplant recipients (SRTR): 1994 to 2016, Medicine (Baltimore), 97, 10.1097/MD.0000000000011518 Haldar, 2019, European liver and intestine transplant association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study, J Hepatol, 71, 313, 10.1016/j.jhep.2019.04.011 Cholankeril, 2017, Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes, Dig Dis Sci, 62, 2915, 10.1007/s10620-017-4684-x Younossi, 2018, Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation, Liver Transpl, 24, 166, 10.1002/lt.25003 Stepanova, 2015, Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis, BMC Gastroenterol, 15, 175, 10.1186/s12876-015-0407-y